Antibody Information
General Information of This Antibody (ID: ANTI0MKGYS)
| Antibody Name | Anti-PTK7 antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | PTK7 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PRO1107 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients had advanced/metastatic PTK7-positive solid tumors (e.g., ovarian, NSCLC, TNBC) with measurable disease, ECOG 0-1, and no prior anti-PTK7 therapy or uncontrolled comorbidities; exclusions included recent ADC progression, active CNS metastases, or infections.
|
||||
| Administration Dosage |
PRO1107 monotherapy in escalating doses in Part A and at the two recommended phase 2 doses in Part B
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06171789 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study assessed adverse events, lab abnormalities, and dose-limiting toxicities over 1 year, including type, incidence, severity, and relatedness.
|
||||
| Other Endpoint |
Key efficacy outcomes included ORR, DCR, PFS, and duration of response per RECIST v1.1, alongside pharmacokinetic parameters (AUC, Cmax, Tmax, t1/2, Ctrough) for PRO1107 over 1 year.
|
||||